TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01959178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
Study: NCT04594135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD5 CAR T cells
Description: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
Study: NCT03121300

Intervention type: OTHER
Intervention: CT Scan
Description: Quantitative lung SPECT-CT

Intervention type: OTHER
Intervention: Lung CT
Description: CT lung ventilation

Intervention type: OTHER
Intervention: MRI
Description: DCE MRI

Intervention type: OTHER
Intervention: Walk Test
Description: 6 minute hall walk test

Intervention type: OTHER
Intervention: SGRQ
Description: St. George Respiratory Questionnaire

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Blood Draw

Intervention type: OTHER
Intervention: Toxicity
Description: Toxicity Evaluation

Intervention type: OTHER
Intervention: Cardiac Assessment
Description: Cardiac MRI Scan
Study: NCT01296971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1'000/1'200 mg daily orally, 24 - 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1'000/1'200 mg daily orally, 24 - 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 800 mg daily orally, 16 - 48 weeks
Study: NCT00383669

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins (including B, C and E)
Description: One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins B, C and E
Description: One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
Study: NCT04805476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive mechanical ventilation
Description: Prophylactic non invasive mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP
Description: GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
Study: NCT01288170

Intervention type: DRUG
Group type: OTHER
Intervention: Nebcinal Tobi

Intervention type: DRUG
Group type: OTHER
Intervention: Tobi Nebcinal
Study: NCT00413673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRK
Description: PRK
Study: NCT02506855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Study: NCT03440515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone treatment for severe skin rash induced by imatinib
Study: NCT02198859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study: NCT01168843

Intervention type: OTHER
Intervention: computerized analysis of sonographic images
Description: Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
Study: NCT03233828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 500,000 IU in 0.1mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.1 mL of sterile saline solution (0.9% m/v)
Study: NCT01672086

Intervention type: DEVICE
Intervention: Stelkast Surpass Acetabular System implant
Study: NCT01146184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible endoscope and Ethicon Manually Articulating Device
Description: Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
Study: NCT03703960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnotic analgesia
Description: classic three-step hypnosis procedure (induction, trance and return to consciousness).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: calm music conducive to relaxation
Study: NCT00853190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
Study: NCT03565458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: forxiga, dapagliflozin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: jardiance 25mg, empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: jardiance 25mg, empagliflozin
Study: NCT04069871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trans-cutaneous electrical nerve stimulation.
Description: • Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Patients in the control group will receive sham TENS.
Study: NCT02496936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: High saturated fatty acid/SFA oil source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: High monounsaturated fatty acid/MUFA oil source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA-LA
Description: High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALA
Description: High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCn3
Description: High polyunsaturated fatty acid (omega-3)/LCn3 oil source
Study: NCT01069991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education group
Description: Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait list control group
Description: No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
Study: NCT00605761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 50 mg treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 150 mg treatment
Study: NCT03320421

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used.
Study: NCT00848107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: sustained release tablet; BID dosing; up to 16 mg BID
Study: NCT00077545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT01980966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA549A
Description: IV dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir [Tamiflu]
Description: Orally b.i.d, 5 days
Study: NCT01404715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
Study: NCT04324099

Intervention type: OTHER
Intervention: Emotion Regulation Questionnaire (for children)
Description: 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)

Intervention type: OTHER
Intervention: Basic Empathy Scale (BES) (for children)
Description: The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.

Intervention type: OTHER
Intervention: Basic Empathy Scale (BES) (for children)
Description: The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.

Intervention type: OTHER
Intervention: Basic Empathy Scale (BES) (for children)
Description: The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.

Intervention type: OTHER
Intervention: Pubertal Development Scale (PDS) (for children)
Description: self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.

Intervention type: OTHER
Intervention: Pubertal Development Scale (PDS) (for children)
Description: self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
Study: NCT01404715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: A single oral dose of 600 mg of imatinib
Study: NCT02235038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
Study: NCT01762930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Study: NCT04324099

Intervention type: OTHER
Intervention: Pubertal Development Scale (PDS) (for children)
Description: self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
Study: NCT01762930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shanchol
Description: Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
Study: NCT02802449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 Hydroxy- Vitamin D3 [25 (OH) D3]
Description: Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04324099

Intervention type: OTHER
Intervention: Alabama Parenting Questionnaire (APQ) (for parents)
Description: The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)

Intervention type: OTHER
Intervention: Alabama Parenting Questionnaire (APQ) (for parents)
Description: The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)

Intervention type: OTHER
Intervention: Alabama Parenting Questionnaire (APQ) (for parents)
Description: The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
Study: NCT04016220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
Study: NCT03590392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik
Description: ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik
Description: ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik
Description: ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
Study: NCT02272634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPL-001 80 mg
Description: twice daily \[BID\]
Study: NCT03377205

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression screws and neutralization plate
Description: Open reduction and internal fixation with screws and plate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumed Fibular Rod System
Description: intramedullary nailing of fibula
Study: NCT02874534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Treatment will consist of 15 weekly 45-minute sessions.
Study: NCT00853190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Description: Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
Study: NCT03137017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrent Tablet
Description: Single oral dose in one of the four cross-over trial periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrent Tablet
Description: Single oral dose in one of the four cross-over trial periods.
Study: NCT00455936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib 250mg tablet/ QD daily until Progression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
Study: NCT03565250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self understanding interview
Description: semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self understanding interview
Description: semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
Study: NCT03246516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire
Study: NCT05746013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.